News from n-lorem foundation A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jan 26, 2021, 05:00 ET n-Lorem Foundation Celebrates One-Year Anniversary as First and Only Organization to Offer Free, Personalized Treatment to Ultra-Rare Disease Patients

n-Lorem Foundation, the first and only nonprofit organization whose mission is to create experimental antisense oligonucleotide (ASO) treatments for...

Dec 10, 2020, 07:05 ET n-Lorem Foundation Receives $500,000 Donation to Develop Individualized Treatments for Patients with Ultra-Rare Diseases

n-Lorem Foundation, a nonprofit organization that provides free, lifetime supplies of individualized RNA-targeted medicines to patients living with...

Apr 14, 2020, 07:05 ET n-Lorem Foundation receives $500,000 donation for providing experimental antisense medicines to treat patients with ultra-rare diseases

The n-Lorem Foundation announced today it has received a pledge of $500,000 from Paul and Andrea Compton in support of the n-Lorem Foundation's...

Mar 19, 2020, 14:00 ET Korea Institute of Toxicology joins growing list of global partners supporting n-Lorem's efforts to deliver treatments for patients with ultra-rare diseases

The n-Lorem Foundation announced today that the Korea Institute of Toxicology (KIT) has become the latest institute to join in support of the n-Lorem ...

Mar 12, 2020, 14:42 ET n-Lorem Foundation receives additional support for providing "n of 1" experimental antisense medicines to treat patients with ultra-rare diseases

The n-Lorem Foundation announced today it has received an initial pledge of $500,000 from Mark Lampert in support of the n-Lorem Foundation's efforts ...

Jan 08, 2020, 07:05 ET n-Lorem Foundation established to charitably provide antisense medicines to treat patients with ultra-rare diseases

The n-Lorem Foundation announced today its official launch as a nonprofit organization established to provide advanced, experimental RNA-targeted...